You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNortriptyline
Accession NumberDB00540  (APRD00602)
TypeSmall Molecule
GroupsApproved
Description

Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Nortriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use).

Structure
Thumb
Synonyms
10,11-dihydro-N-Methyl-5H-dibenzo[a,D]cycloheptene-delta(5,gamma)-propylamine
3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine
Ateben
Avantyl
Aventyl
Demethylamitriptyline
Desmethylamitriptyline
Noritren
Nortriptyline
Psychostyl
Sensaval
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-nortriptylinecapsule10 mgoralAvanstra Inc2011-11-282014-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ava-nortriptylinecapsule25 mgoralAvanstra Inc2011-11-282014-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Aventylcapsule25 mgoralAa Pharma Inc1965-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Aventylcapsule10 mgoralAa Pharma Inc1965-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-nortriptyline 10mg Capsulescapsule10 mgoralDominion Pharmacal1995-10-012014-09-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-nortriptyline 25mg Capsulescapsule25 mgoralDominion Pharmacal1995-10-012014-09-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Gen-nortriptyline Capsules 10mgcapsule10 mgoralGenpharm Ulc1997-09-052009-08-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Gen-nortriptyline Capsules 25mgcapsule25 mgoralGenpharm Ulc1997-09-052009-08-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nortriptylinecapsule25 mgoralPharmel Inc1998-06-042014-09-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nortriptylinecapsule10 mgoralPharmel Inc1998-06-042014-09-08Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nortriptyline-10capsule10 mgoralPro Doc Limitee2008-03-07Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nortriptyline-25capsule25 mgoralPro Doc Limitee2008-03-07Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Norventylcapsule25 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Norventylcapsule10 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-nortriptyline - Cap 10mgcapsule10 mgoralNu Pharm Inc1996-07-232012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-nortriptyline - Cap 25mgcapsule25 mgoralNu Pharm Inc1996-07-262012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Pamelorcapsule10 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pamelorcapsule75 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pamelorcapsule50 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pamelorcapsule25 mg/1oralMallinckrodt, Inc.2010-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
PMS-nortriptylinecapsule25 mgoralPharmascience Inc1996-08-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-nortriptylinecapsule10 mgoralPharmascience Inc1996-08-23Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-nortriptylinecapsule25 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-10-212009-07-17Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-nortriptylinecapsule10 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-10-212009-07-17Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-nortriptylinecapsule25 mgoralTeva Canada Limited1998-09-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-nortriptylinecapsule10 mgoralTeva Canada Limited1998-09-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nortriptyline - Cap 10mgcapsule10 mgoralApotex Inc1996-09-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-nortriptyline - Cap 25mgcapsule25 mgoralApotex Inc1996-09-26Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nortriptyline Hydrochloridecapsule10 mg/1oralAidarex Pharmaceuticals LLC1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralAphena Pharma Solutions Tennessee, Llc1995-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralClinical Solutions Wholesale1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralTeva Pharmaceuticals USA Inc1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralUnit Dose Services1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2014-06-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2010-11-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralbryant ranch prepack2010-11-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralMedsource Pharmaceuticals2000-05-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralPreferred Pharmaceuticals Inc.2015-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2011-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralbryant ranch prepack1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralKAISER FOUNDATION HOSPITALS2014-06-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralMedsource Pharmaceuticals1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralCardinal Health2011-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2011-12-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralbryant ranch prepack1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridesolution10 mg/5mLoralPharmaceutical Associates, Inc.2000-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralPreferred Pharmaceuticals, Inc.2015-05-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralSTAT Rx USA LLC1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralPhysicians Total Care, Inc.2009-06-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2011-09-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralProficient Rx LP1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralTeva Pharmaceuticals USA Inc1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralREMEDYREPACK INC.2014-08-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralBlenheim Pharmacal, Inc.2013-11-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralPhysicians Total Care, Inc.2008-11-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2013-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralCarilion Materials Management1995-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralProficient Rx LP1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralTeva Pharmaceuticals USA Inc1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralUnit Dose Services1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralAidarex Pharmaceuticals LLC1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralAmerican Health Packaging1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralREMEDYREPACK INC.2011-06-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralProficient Rx LP1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralPhysicians Total Care, Inc.2004-02-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralDispensing Solutions, Inc.1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralAidarex Pharmaceuticals LLC1995-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralClinical Solutions Wholesale1995-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralAidarex Pharmaceuticals LLC1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralAmerican Health Packaging1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralClinical Solutions Wholesale1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralTeva Pharmaceuticals USA Inc1995-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralUnit Dose Services1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralProficient Rx LP1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule50 mg/1oralWatson Laboratories, Inc.1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralPhysicians Total Care, Inc.1993-09-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2011-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralbryant ranch prepack1992-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule75 mg/1oralRebel Distributors Corp1992-03-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralClinical Solutions Wholesale1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nortriptyline Hydrochloridecapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AllegronNot Available
NoritrenNot Available
NorpressNot Available
NortrilenNot Available
SensovalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nortriptyline Hydrochloride
Thumb
  • InChI Key: SHAYBENGXDALFF-UHFFFAOYSA-N
  • Monoisotopic Mass: 299.144077416
  • Average Mass: 299.838
DBSALT000641
Categories
UNIIBL03SY4LXB
CAS number72-69-5
WeightAverage: 263.3767
Monoisotopic: 263.167399677
Chemical FormulaC19H21N
InChI KeyInChIKey=PHVGLTMQBUFIQQ-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
IUPAC Name
methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis.
PharmacodynamicsSimilar to protriptyline, nortriptyline is a tricyclic antidepressant of the dibenzocycloheptene type and is the active metabolite of amitriptyline.
Mechanism of actionIt is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake.
AbsorptionWell absorbed from the GI tract. Peak plasma concentrations occur 7-8.5 hours following oral administration.
Volume of distributionNot Available
Protein bindingHighly protein-bound in plasma and tissues.
Metabolism

Undergoes hepatic metabolism via the same pathway as other TCAs.

SubstrateEnzymesProduct
Nortriptyline
E-10-HydroxynortriptylineDetails
Nortriptyline
DesmethylnortriptylineDetails
E-10-Hydroxynortriptyline
Not Available
E-10-HydroxydesmethylnortriptylineDetails
Desmethylnortriptyline
E-10-HydroxydesmethylnortriptylineDetails
Route of eliminationApproximately one-third of a single orally administered dose is excreted in urine within 24 hours. Small amounts are excreted in feces via biliary elimination.
Half life16 to 90+ hours
ClearanceNot Available
ToxicitySymptoms of overdose include cardiac dysrhythmias, severe hypotension, shock, congestive heart failure, pulmonary edema, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 Not AvailableT Allele, homozygousPostural hypotension12082591
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9478
Caco-2 permeable+0.774
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8876
P-glycoprotein inhibitor IIInhibitor0.5376
Renal organic cation transporterInhibitor0.6903
CYP450 2C9 substrateNon-substrate0.7508
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5593
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5194
Ames testNon AMES toxic0.5315
CarcinogenicityNon-carcinogens0.9182
BiodegradationReady biodegradable0.5
Rat acute toxicity2.7513 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5809
hERG inhibition (predictor II)Inhibitor0.7763
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Tyco healthcare group lp
  • Ranbaxy pharmaceuticals inc
  • Pharmaceutical assoc inc
  • Taro pharmaceutical industries ltd
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg
Capsuleoral25 mg
Capsuleoral10 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Capsuleoral75 mg/1
Solutionoral10 mg/5mL
Prices
Unit descriptionCostUnit
Pamelor 30 10 mg capsule Bottle750.05USD bottle
Pamelor 30 25 mg capsule Bottle750.05USD bottle
Pamelor 30 50 mg capsule Bottle750.05USD bottle
Pamelor 10 mg/5ml Solution 480ml Bottle325.97USD bottle
Pamelor 10 mg capsule24.04USD capsule
Pamelor 25 mg capsule24.04USD capsule
Pamelor 50 mg capsule24.04USD capsule
Pamelor 75 mg capsule19.34USD capsule
Nortriptyline hcl powder11.09USD g
Nortriptyline hcl 75 mg capsule1.33USD capsule
Nortriptyline hcl 50 mg capsule0.94USD capsule
Nortriptyline hcl 25 mg capsule0.6USD capsule
Aventyl 25 mg Capsule0.48USD capsule
Nortriptyline HCl 10 mg/5ml Solution0.4USD ml
Nortriptyline hcl 10 mg capsule0.28USD capsule
Apo-Nortriptyline 25 mg Capsule0.27USD capsule
Novo-Nortriptyline 25 mg Capsule0.27USD capsule
Nu-Nortriptyline 25 mg Capsule0.27USD capsule
Pms-Nortriptyline 25 mg Capsule0.27USD capsule
Aventyl 10 mg Capsule0.24USD capsule
Apo-Nortriptyline 10 mg Capsule0.13USD capsule
Novo-Nortriptyline 10 mg Capsule0.13USD capsule
Nu-Nortriptyline 10 mg Capsule0.13USD capsule
Pms-Nortriptyline 10 mg Capsule0.13USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point213-215 °CNot Available
logP4.51BRODIN,A (1974)
pKa10.1SANGSTER (2004)
Predicted Properties
PropertyValueSource
Water Solubility0.000874 mg/mLALOGPS
logP4.65ALOGPS
logP4.43ChemAxon
logS-5.5ALOGPS
pKa (Strongest Basic)10.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity96.21 m3·mol-1ChemAxon
Polarizability31.87 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.76 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-zac0000000-15f73e5232a0e230f41bView in MoNA
References
Synthesis Reference

Abraham Nudelman, “ACID ADDITION SALT OF A NORTRIPTYLINE-GABA CONJUGATE AND A PROCESS OF PREPARING SAME.” U.S. Patent US20130184347, issued July 18, 2013.

US20130184347
General References
  1. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D: A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998 Oct 12;158(18):2035-9. Pubmed
External Links
ATC CodesN06AA10
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (420 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Nortriptyline can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Acetophenazine.
AclidiniumAclidinium may increase the anticholinergic activities of Nortriptyline.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Nortriptyline.
AmisulprideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amisulpride.
AmphetamineNortriptyline may increase the stimulatory activities of Amphetamine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nortriptyline.
AzelastineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Nortriptyline.
BatimastatThe serum concentration of Nortriptyline can be increased when it is combined with Batimastat.
BenzquinamideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Benzquinamide.
Botulinum Toxin Type ANortriptyline may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BNortriptyline may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
BuprenorphineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BupropionThe metabolism of Nortriptyline can be decreased when combined with Bupropion.
ButabarbitalThe metabolism of Nortriptyline can be increased when combined with Butabarbital.
ButethalThe metabolism of Nortriptyline can be increased when combined with Butethal.
CarbamazepineThe metabolism of Nortriptyline can be increased when combined with Carbamazepine.
CarphenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Carphenazine.
CathinoneNortriptyline may increase the stimulatory activities of Cathinone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorpromazine.
ChlorpropamideNortriptyline may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorprothixene.
CimetidineThe metabolism of Nortriptyline can be decreased when combined with Cimetidine.
Cimetropium BromideNortriptyline may increase the anticholinergic activities of Cimetropium Bromide.
CinacalcetThe serum concentration of Nortriptyline can be increased when it is combined with Cinacalcet.
CitalopramThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Citalopram.
ClozapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clozapine.
CobicistatThe serum concentration of Nortriptyline can be increased when it is combined with Cobicistat.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nortriptyline.
DarunavirThe serum concentration of Nortriptyline can be increased when it is combined with Darunavir.
DesmopressinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Nortriptyline.
DicoumarolNortriptyline may increase the anticoagulant activities of Dicoumarol.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Nortriptyline.
DofetilideNortriptyline may increase the QTc-prolonging activities of Dofetilide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DuloxetineDuloxetine may increase the serotonergic activities of Nortriptyline.
EluxadolineNortriptyline may increase the activities of Eluxadoline.
EscitalopramThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.
EthanolNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FencamfamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fencamfamine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nortriptyline.
FlupentixolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nortriptyline.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Glucagon recombinant.
GoserelinNortriptyline may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Nortriptyline.
HaloperidolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Haloperidol.
HeptabarbitalThe metabolism of Nortriptyline can be increased when combined with Heptabarbital.
HexobarbitalThe metabolism of Nortriptyline can be increased when combined with Hexobarbital.
HydrocodoneNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Nortriptyline.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Nortriptyline.
IsoflurophateThe serum concentration of Nortriptyline can be increased when it is combined with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Nortriptyline.
LeuprolideNortriptyline may increase the QTc-prolonging activities of Leuprolide.
LinezolidLinezolid may increase the serotonergic activities of Nortriptyline.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Nortriptyline.
LithiumLithium may increase the neurotoxic activities of Nortriptyline.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nortriptyline.
LoxapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Loxapine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
MesoridazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Mesoridazine.
MethohexitalThe metabolism of Nortriptyline can be increased when combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methotrimeprazine.
Methylene blueNortriptyline may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nortriptyline.
MetyrosineNortriptyline may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Nortriptyline.
MidodrineNortriptyline may increase the activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Nortriptyline.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
MirabegronThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Mirabegron.
MolindoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Morphine.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Nortriptyline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
NicorandilNortriptyline may increase the hypotensive activities of Nicorandil.
OlanzapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ondansetron.
OrciprenalineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Orciprenaline.
OrphenadrineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PaliperidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Paliperidone.
PanobinostatThe serum concentration of Nortriptyline can be increased when it is combined with Panobinostat.
ParaldehydeNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.
Peginterferon alfa-2bThe serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Nortriptyline can be increased when combined with Pentobarbital.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
PerphenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Nortriptyline.
PimozideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Piperacetazine.
Potassium ChlorideNortriptyline may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleNortriptyline may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Nortriptyline.
PrimidoneThe metabolism of Nortriptyline can be increased when combined with Primidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Nortriptyline.
PromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Quetiapine.
QuinidineNortriptyline may increase the QTc-prolonging activities of Quinidine.
RamosetronNortriptyline may increase the activities of Ramosetron.
RemoxiprideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Risperidone.
RitonavirThe metabolism of Nortriptyline can be decreased when combined with Ritonavir.
RopiniroleNortriptyline may increase the sedative activities of Ropinirole.
RotigotineNortriptyline may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nortriptyline.
SecobarbitalThe metabolism of Nortriptyline can be increased when combined with Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Nortriptyline.
SertindoleThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Nortriptyline.
SimeprevirThe serum concentration of Nortriptyline can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
St. John's WortThe metabolism of Nortriptyline can be increased when combined with St. John's Wort.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Nortriptyline.
SuvorexantNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Nortriptyline can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Nortriptyline.
TerbinafineThe metabolism of Nortriptyline can be decreased when combined with Terbinafine.
ThalidomideNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Thiothixene.
TiclopidineThe metabolism of Nortriptyline can be decreased when combined with Ticlopidine.
TiotropiumNortriptyline may increase the anticholinergic activities of Tiotropium.
TopiramateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Topiramate.
TramadolNortriptyline may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Nortriptyline.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Nortriptyline.
TrifluoperazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Triflupromazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Nortriptyline.
Valproic AcidThe serum concentration of Nortriptyline can be increased when it is combined with Valproic Acid.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Nortriptyline.
ZiprasidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziprasidone.
ZolpidemNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Take with food to reduce irritation.

Targets

1. Sodium-dependent noradrenaline transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent noradrenaline transporter P23975 Details

References:

  1. Roubert C, Cox PJ, Bruss M, Hamon M, Bonisch H, Giros B: Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J Biol Chem. 2001 Mar 16;276(11):8254-60. Epub 2000 Nov 22. Pubmed
  2. Roubert C, Sagne C, Kapsimali M, Vernier P, Bourrat F, Giros B: A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes). Mol Pharmacol. 2001 Sep;60(3):462-73. Pubmed
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. Pubmed
  4. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK: Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006 Oct 4;296(13):1609-18. Pubmed
  5. Barker EL, Blakely RD: Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996 Oct;50(4):957-65. Pubmed
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed

2. Sodium-dependent serotonin transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent serotonin transporter P31645 Details

References:

  1. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. Pubmed
  2. Wisner KL, Hanusa BH, Perel JM, Peindl KS, Piontek CM, Sit DK, Findling RL, Moses-Kolko EL: Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol. 2006 Aug;26(4):353-60. Pubmed
  3. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90. Pubmed
  4. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. Pubmed
  5. Rausch JL, Moeller FG, Johnson ME: Initial platelet serotonin (5-HT) transport kinetics predict nortriptyline treatment outcome. J Clin Psychopharmacol. 2003 Apr;23(2):138-44. Pubmed
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed

3. 5-hydroxytryptamine receptor 2A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

4. 5-hydroxytryptamine receptor 1A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1A P08908 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

5. Histamine H1 receptor

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Histamine H1 receptor P35367 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Sadava D, Wilmington K: Tricyclic antidepressant drugs affect histamine receptors in human leukocytes. Life Sci. 1984 Dec 17;35(25):2545-8. Pubmed

6. Alpha-1A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. Epub 2010 Apr 2. Pubmed

7. Alpha-1D adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1D adrenergic receptor P25100 Details

References:

  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. Epub 2010 Apr 2. Pubmed

8. Muscarinic acetylcholine receptor M1

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M1 P11229 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

9. Muscarinic acetylcholine receptor M2

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M2 P08172 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

10. Muscarinic acetylcholine receptor M3

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M3 P20309 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

11. Muscarinic acetylcholine receptor M4

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M4 P08173 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

12. Muscarinic acetylcholine receptor M5

Kind: Protein

Organism: Human

Pharmacological action: no

Actions: antagonist

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M5 P08912 Details

References:

  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. Pubmed

13. 5-hydroxytryptamine receptor 2C

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2C P28335 Details

References:

  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. Pubmed

14. 5-hydroxytryptamine receptor 6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 6 P50406 Details

References:

  1. National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Oct 3]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from: http://pdsp.med.unc.edu/pdsp.php
  2. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.
  3. Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. Pubmed

15. Alpha-1B adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. Pubmed

16. Alpha-2 adrenergic receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2A adrenergic receptor P08913 Details
Alpha-2B adrenergic receptor P18089 Details
Alpha-2C adrenergic receptor P18825 Details

References:

  1. National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Oct 3]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from: http://pdsp.med.unc.edu/pdsp.php
  2. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.

17. Beta adrenergic receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Beta-1 adrenergic receptor P08588 Details
Beta-2 adrenergic receptor P07550 Details
Beta-3 adrenergic receptor P13945 Details

References:

  1. National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Oct 3]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from: http://pdsp.med.unc.edu/pdsp.php
  2. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.

18. D(2) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Peroutka SJ, Snyder SH: Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982 Mar 20;1(8273):658-9. Pubmed
  2. National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Oct 3]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from: http://pdsp.med.unc.edu/pdsp.php
  3. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.

19. Sigma receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Membrane-associated progesterone receptor component 1 O00264 Details
Sigma non-opioid intracellular receptor 1 Q99720 Details

References:

  1. National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Oct 3]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from: http://pdsp.med.unc.edu/pdsp.php
  2. Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.

20. 5-hydroxytryptamine receptor 1C

Kind: Protein

Organism: Rat

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2C P08909 Details

References:

  1. Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE: Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol. 1993 Feb 9;231(2):223-9. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. Epub 2008 Feb 14. Pubmed
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  5. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. Pubmed
  6. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. Pubmed

2. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. Epub 2008 Feb 14. Pubmed
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. Pubmed

3. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. Epub 2008 Feb 14. Pubmed
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  4. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. Pubmed

4. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. Pubmed

5. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

6. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. Epub 2008 Feb 14. Pubmed

7. Prostaglandin G/H synthase 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

8. Cytochrome P450 2E1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: Protein

Organism: Human

Pharmacological action: no

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. Pubmed

2. Alpha-1-acid glycoprotein 1

Kind: Protein

Organism: Human

Pharmacological action: no

Components

Name UniProt ID Details
Alpha-1-acid glycoprotein 1 P02763 Details

References:

  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. Pubmed
  2. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11